Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Does Methylene Blue Satisfy an Option in COVID-19 ARDS

Author(s): Sri Hari Tanguturi Yella, Sree Sudha Tanguturi Yella*, Kota Sesha Brahma Shree Krishna Sasanka and Pugazhenthan Thangaraju

Volume 22, Issue 6, 2022

Published on: 23 May, 2022

Article ID: e170322202339 Pages: 4

DOI: 10.2174/1871526522666220317155947

Price: $65

Abstract

Background: In COVID-19, the respiratory tract is usually affected by SARS-CoV-2 infection. Due to viral transmission in the blood and an overwhelming inflammatory response, including cytokine storm, the condition can progress to acute respiratory distress syndrome and failure. Methylene blue is the only medicine that has been shown to reduce the excessive generation of reactive species and cytokines.

Case Presentation: A 51-year-old male patient came to the hospital with shortness of breath. At room air, the patient was having 70% Spo2. The patient was treated with a noninvasive ventilator (NIV) and Standard of care (SOC). Due to prolonged hypoxia and respiratory distress, the patient was treated with NIV and the methylene blue (MB) was given in a humidifier for 5 days.

Result: Methylene blue resulted in a significant decrease in respiratory distress and a steep rise in Spo2.

Conclusion: We suggest trying methylene blue as an additional intervention in COVID-related acute respiratory distress to avoid the disease's devastating consequences.

Keywords: COVID-19, methylene blue, acute respiratory distress, non-invasive ventilator, the standard of care, Spo2.

Graphical Abstract

[1]
Shenoy N, Luchtel R, Gulani P. Considerations for target oxy-gen saturation in COVID-19 patients: are we under-shooting? BMC Med 2020; 18(1): 260.
[http://dx.doi.org/10.1186/s12916-020-01735-2] [PMID: 32814566]
[2]
Perkins GD, Couper K, Connolly B, et al. RECOVERY- respira-tory support: Respiratory strategies for patients with suspected or proven covid-19 respiratory failure; continuous positive air-way pressure, high-flow nasal oxygen, and standard care: A structured summary of a study protocol for a randomised con-trolled trial. Trials 2020; 21(1): 687.
[http://dx.doi.org/10.1186/s13063-020-04617-3] [PMID: 32727624]
[3]
Chan DS, Yang H, Kwan MH, et al. Structure-based optimiza-tion of FDA-approved drug methylene blue as a c-myc G-quadruplex DNA stabilizer. Biochimie 2011; 93(6): 1055-64.
[http://dx.doi.org/10.1016/j.biochi.2011.02.013] [PMID: 21377506]
[4]
Komlódi T, Tretter L. Methylene blue stimulates substrate-level phosphorylation catalysed by succinyl-CoA ligase in the citric acid cycle. Neuropharmacology 2017; 123: 287-98.
[http://dx.doi.org/10.1016/j.neuropharm.2017.05.009] [PMID: 28495375]
[5]
Tranquada RE, Bernstein S, Grant WJ. Intravenous methylene blue in the therapy of lactic acidosis. Arch Intern Med 1964; 114: 13-25.
[http://dx.doi.org/10.1001/archinte.1964.03860070059003] [PMID: 14156066]
[6]
Levine S. Interaction between ethyl methylene blue and cya-nide-induced increases in blood lactate. J Lab Clin Med 1977; 89(3): 632-9.
[PMID: 839120]
[7]
Gendrot M, Andreani J, Duflot I, et al. Methylene blue inhibits replication of SARS-CoV-2 in vitro. Int J Antimicrob Agents 2020; 56(6): 106202.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106202] [PMID: 33075512]
[8]
Wang Z, Zhang S, Xiao Y, et al. NLRP3 inflammasome and inflammatory diseases. Oxid Med Cell Longev 2020; 2020: 4063562.
[http://dx.doi.org/10.1155/2020/4063562] [PMID: 32148650]
[9]
Franchi L, Muñoz-Planillo R, Núñez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol 2012; 13(4): 325-32.
[http://dx.doi.org/10.1038/ni.2231] [PMID: 22430785]
[10]
Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol 2019; 10: 50.
[http://dx.doi.org/10.3389/fmicb.2019.00050] [PMID: 30761102]
[11]
Akaike T, Noguchi Y, Ijiri S, et al. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc Natl Acad Sci USA 1996; 93(6): 2448-53.
[http://dx.doi.org/10.1073/pnas.93.6.2448] [PMID: 8637894]
[12]
Perrone LA, Belser JA, Wadford DA, Katz JM, Tumpey TM. Inducible nitric oxide contributes to viral pathogenesis follow-ing highly pathogenic influenza virus infection in mice. J Infect Dis 2013; 207(10): 1576-84.
[http://dx.doi.org/10.1093/infdis/jit062] [PMID: 23420903]
[13]
Rhaleb NE, Dion S, Barabé J, et al. Receptors for kinins in iso-lated arterial vessels of dogs. Eur J Pharmacol 1989; 162(3): 419-27.
[http://dx.doi.org/10.1016/0014-2999(89)90332-4] [PMID: 2545457]
[14]
Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide syn-thesis by methylene blue. Biochem Pharmacol 1993; 45(2): 367-74.
[http://dx.doi.org/10.1016/0006-2952(93)90072-5] [PMID: 7679577]
[15]
Alamdari DH, Moghaddam AB, Amini S, et al. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. Eur J Pharmacol 2020; 885: 173494.
[http://dx.doi.org/10.1016/j.ejphar.2020.173494] [PMID: 32828741]
[16]
Tian WF, Zeng S, Sheng Q, et al. Methylene blue protects the isolated rat lungs from ischemia-reperfusion injury by attenuat-ing mitochondrial oxidative damage. Lung 2018; 196(1): 73-82.
[http://dx.doi.org/10.1007/s00408-017-0072-8] [PMID: 29204685]
[17]
Riedel W, Lang U, Oetjen U, Schlapp U, Shibata M. Inhibition of oxygen radical formation by methylene blue, aspirin, or al-pha-lipoic acid, prevents bacterial-lipopolysaccharide-induced fever. Mol Cell Biochem 2003; 247(1-2): 83-94.
[http://dx.doi.org/10.1023/A:1024142400835] [PMID: 12841635]
[18]
Salaris SC, Babbs CF, Voorhees WD III. Methylene blue as an inhibitor of superoxide generation by xanthine oxidase. A po-tential new drug for the attenuation of ischemia/reperfusion in-jury. Biochem Pharmacol 1991; 42(3): 499-506.
[http://dx.doi.org/10.1016/0006-2952(91)90311-R] [PMID: 1650213]
[19]
Miclescu A, Wiklund L. Methylene blue, an old drug with new indications. J Rom Anest Terap Int 2010; 17: 35-41.
[20]
Haynes RK, Chan WC, Wong HN, et al. Facile oxidation of leucomethylene blue and dihydroflavins by artemisinins: rela-tionship with flavoenzyme function and antimalarial mechanism of action. ChemMedChem 2010; 5(8): 1282-99.
[http://dx.doi.org/10.1002/cmdc.201000225] [PMID: 20629071]
[21]
Lin ZH, Wang SY, Chen LL, et al. Methylene blue mitigates acute neuroinflammation after spinal cord injury through inhib-iting NLRP3inflammasome activation in microglia. Front Cell Neurosci 2017; 11: 391.
[http://dx.doi.org/10.3389/fncel.2017.00391] [PMID: 29311826]
[22]
A treatment algorithm for managing adult cases of COVID-19 Available at: https://www.mohfw.gov.in/pdf/COVID19ClinicalManagementProtocolAlgorithmAdults19th May2021.pdf
[23]
Abd-Elsalam S, Soliman S, Esmail ES, et al. Do zinc supple-ments enhance the clinical efficacy of hydroxychloroquine?: A randomized, multicenter trial. Biol Trace Elem Res 2021; 199(10): 3642-6.
[http://dx.doi.org/10.1007/s12011-020-02512-1] [PMID: 33247380]
[24]
Abd-Elsalam S, Ahmed OA, Mansour NO, et al. Remdesivir efficacy in COVID-19 treatment: A randomized controlled trial. Am J Trop Med Hyg 2021; 106(3): 886-90.
[http://dx.doi.org/10.4269/ajtmh.21-0606] [PMID: 34649223]
[25]
Efficacy of combined Sofosbuvir and Daclatasvir in the treat-ment of COVID-19 patients with pneumonia: a multicenter Egyptian study. Expert Rev Anti Infect Ther 2021; 1-5.
[http://dx.doi.org/10.1080/14787210.2021.1950532]
[26]
Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evalu-ating the efficacy of ivermectin in COVID-19 treatment: A ran-domized controlled study. J Med Virol 2021; 93(10): 5833-8.
[http://dx.doi.org/10.1002/jmv.27122] [PMID: 34076901]
[27]
Dabbous HM, Abd-Elsalam S, El-Sayed MH, et al. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol 2021; 166(3): 949-54.
[http://dx.doi.org/10.1007/s00705-021-04956-9] [PMID: 33492523]

Rights & Permissions Print Cite
Article Metrics
26
1
© 2024 Bentham Science Publishers | Privacy Policy